ZEALAND PHARMA/S (NASDAQ:ZEAL) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
Several other equities research analysts have also recently weighed in on ZEAL. Zacks Investment Research upgraded ZEALAND PHARMA/S from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, January 1st. TheStreet upgraded ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a research note on Tuesday, January 22nd. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of ZEALAND PHARMA/S in a research note on Thursday, March 7th. Finally, Goldman Sachs Group cut ZEALAND PHARMA/S from a “buy” rating to a “neutral” rating in a research note on Monday, December 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $24.00.
ZEAL stock traded down $0.23 during trading on Friday, hitting $15.37. 434 shares of the company’s stock were exchanged, compared to its average volume of 4,686. The stock has a market cap of $475.76 million, a price-to-earnings ratio of -10.39 and a beta of 2.21. ZEALAND PHARMA/S has a 52-week low of $11.51 and a 52-week high of $18.91.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Recommended Story: What is the Coverage Ratio?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.